Hypocomplementaemia and Disease

Abramson N. Alper C. A. Lachmann P. J. Rosen F. S. Jandle J. H. (1971). Deficiency of C3 inactivator in man. Journal of Immunology, 107, 19.

Agnello V. de Bracco M. M. E. Kunkel H. G. (1972). Hereditary C2-deficiency with some manifestations of systemic lupus erythematosus. Journal of Immunology, 108, 837.

Bokisch V. A. Dierich M. P. Müller-Eberhard H. J. (1975). The third component of complement (C3); structural properties in relation to functions. Proceedings of the National Academy of the Sciences of the United States of America, 72, 1989.

Bokisch V. A. Müller-Eberhard H. J. (1970). Anaphylotoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. Journal of Clinical Investigation, 49, 2427.

Borsos T. Rapp H. (1965). Hemolysin titration based on fixation of the activated first component of complement: evidence that one molecule of hemolysin suffices to sensitize an erythrocyte. Journal of Immunology, 95, 559.

Borsos T. Rapp H. J. Mayer M. M. (1961). Studies on the second component of complement. II. The nature of the decay of EAC 142. Journal of Immunology, 87, 326.

Boyer J. T. Gall E. P. Norman M. E. Nilsson U. R. Zimmerman T. S. (1975). Hereditary deficiency of the seventh component of complement. Journal of Clinical Investigation, 56, 905.

Cochrane G. C. Müller-Eberhard H. J. (1968). The derivation of 2 distinct anaphylotoxin activities from the third and fifth component of human complement. Journal of Experimental Medicine, 127, 371.

Cooper N. R. Jensen S. C. Welsh R. M. Oldstone M. B. A. (1976). Lysis of RNA tumor viruses by human serum: direct antibody-dependent triggering of the classical complement pathway. Journal of Experimental Medicine, 144, 970.

Cooper N. R. Müller-Eberhard H. J. (1970). The reaction mechanism of human C5 in immune haemolysis. Journal of Experimental Medicine, 132, 775.

Daha M. R. Fearon D. T. Austen K. F. (1976). C3 nephritic factor (C3NF): stabilization of fluid phase and cell-bound alternative pathway convertase. Journal of Immunology, 116, 1.

Daniels C. A. Borsos T. Rapp H. J. Snyderman R. Notkins A. L. (1970). Neutralization of sensitised virus by purified components of complement. Proceedings of the National Academy of the Sciences of the United States of America, 65, 528.

Fearon D. T. Austen K. F. (1975). Properdin: binding to C3b and stabilization of the C3b-dependent convertase. Journal of Experimental Medicine, 142, 856.

Gigli I. Nelson R. A. Jr . (1968). Complement dependent immune phagocytosis. I. Requirements for C1, C4, C2, C3. Experimental Cell Research, 51, 45.

Glass D. Raum D. Gibson D. Stillman J. Schur P. H. (1976). Inherited deficiency of the second component of complement. Rheumatic disease associations. Journal of Clinical Investigation, 58, 853.

Jensen J. Snyderman R. Mergenhagen S. E. (1969). Chemotactic acticity, a property of guinea pig C5 anaphylotoxin. In Cellular and humoral mechanisms of anaphylaxis and allergy, pp. 265–278, edited by Movat A. . Basel: Karger.

Klemperer M. R. Rosen F. S. Donaldson V. H. (1969). A polypeptide derived from the second component of complement (C2) which increases vascular permeability. Journal of Clinical Investigation, 48, 44a.

Kolb W. P. Haxby J. A. Arroyave C. Müller-Eberhard H. J. (1972). Molecular analysis of the membrane attack mechanism of complement. Journal of Experimental Medicine, 135, 549.

Leddy J. P. Griggs R. C. Klemperer M. R. Frank M. M. (1975). Hereditary complement (C2) deficiency with dermatomyositis. American Journal of Medicine, 58, 83.

Mayer M. M. (1972). Mechanism of cytolysis by complement. Proceedings of the National Academy of the Sciences of the United States of America, 69, 2954.

McLeod B. Baker P. Gewurz H. (1975). Studies on the inhibition of C56-initiated lysis (reactive lysis). III. Characterization of the inhibitory activity C567-INH and its mode of action. Immunology, 28, 133.

Müller-Eberhard H. J. Götze O. (1972). C3 proactivator convertase and its mode of action. Journal of Experimental Medicine, 135, 1003.

Müller-Eberhard H. J. Lepow I. H. (1965). C1 esterase effect on activity and physical chemical properties of the fourth component of complement. Journal of Experimental Medicine, 121, 819.

Müller-Eberhard H. J. Polley N. J. Calcott M. A. (1967). Formation and functional significance of a molecular complex derived from the second and fourth component of human complement. Journal of Experimental Medicine, 125, 359.

Nelson R. A. (1953). The immune adherence phenomenon. An immunologically specific reaction between micro-organisms and erythrocytes leading to enhanced phagocytosis. Science (Washington, D.C.) 118, 733.

Pangburn M. K. Schreiber R. D. Müller-Eberhard H. J. (1977). Human complement C3b inactivator. Isolation characterization and demonstration of an absolute requirement for the serum protein B1H for cleavage of C3b and C4b in solution. Journal of Experimental Medicine, 146, 257.

Raum D. Glass D. Carpenter C. B. Schur P. H. (1976). C6-deficiency-HLA association. Federation Proceedings, 35, 655 (abstract).

Ruddy S. Austen K. F. (1969). C3b inactivator of man. I. Hemolytic measurement by inactivation of cell-bound C3. Journal of Immunology, 102, 533.

Ruddy S. Carpenter C. B. Müller-Eberhard H. J. Austen K. F. (1967). Complement component levels in hereditary angioneurotic oedema and isolated C2 deficiency in man. In Fifth International Symposium on Immunopathology. Mechanisms of inflammation induced by immune reactions, pp.231–251. edited by Miescher P. A. Grabar P. . Basel/Stuttgart: Schwabe and Co.

Sakai K. Stroud R. M. (1973). Purification of molecular properties and activation of C1 pro-esterase, C1s. Journal of Immunology, 110, 1010.

Schorlemmer H. U. Allison A. C. (1976). Effects of activated complement components on enzyme secretion by macrophages. Immunology, 31, 781.

Schreiber R. D. Götze O. Müller-Eberhard H. J. (1976). Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function. Journal of Experimental Medicine, 144, 1062.

Tauber J. W. Polley N. J. Zabriskie J. B. (1976). Non-specific complement activation by streptococcal structures. II. Properdin-independent initiation of the alternative pathway. Journal of Experimental Medicine, 143, 1352.

Thompson R. A. Lachmann P. J. (1977). A second case of human C3b inhibitor (KAF) deficiency. Clinical and Experimental Immunology, 27, 23.

Valet D. Cooper N. R. (1974). Isolation and characterization of the proenzyme form of the C1s subunit of the first complement component. Journal of Immunology, 112, 339.

Ward P. A. Cochrane C. G. Müller-Eberhard H. J. (1966). Further studies on the chemotactic factors of complement and its formation in vivo. Immunology, London, 11, 141.

Ward P. A. Newman L. J. (1969). A neutrophil chemotactic factor from human C5. Journal of Immunology, 102, 93.

Weiler J. R. Daha M. R. Fearon D. T. Austen K. F. (1976). Control of the amplification of complement by the plasma protein B1H. Proceedings of the National Academy of the Sciences of the United States of America, 73, 3268.

Whaley K. Ruddy S. (1976a). Modulation of the alternative complement pathway by B1H globulin Journal of Experimental Medicine, 144, 1147.

Whaley K. Ruddy S. (1976b). C3b inactivator accelerator. A serum cofactor for C3b inactivator necessary for the full expression of its activity. Journal of Immunology, 116, 1759 (Abstract).

Whaley K. Ruddy S. (1976c). Modulation of C3b haemolytic activity by a plasma protein distinct from C3b inactivator. Science (Washington, D.C.), 193, 1011.

Whaley K. Schur P. H. Ruddy S. (1976). C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase. Journal of Clinical Investigation, 57, 1554.

Whaley K. (1977). The complement system in rheumatoid arthritis and systemic lupus erythematosus. In Research in Rheumatoid Arthritis and Allied Diseases. Edited by Dumonde D. C. Marni R. N. , Lancaster, England: M.T.P. (in press).

Ziegler J. B. Alper C. A. Rosen F. S. Lachmann P. J. Sherington L. (1975). Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency. Journal of Clinical Investigation, 55, 668.